Resolutions from the Annual General Meeting of Novo Nordisk A/S
(Thomson Reuters ONE) -
Bagsværd, Denmark, 23 March 2017 - Today, Novo Nordisk A/S held its Annual
General Meeting, at which the following were adopted:
Financial year 2016 and 2017
* The Company's statutory Annual Report 2016.
* The actual remuneration of the Board of Directors for 2016 and the
remuneration level for 2017.
* The final dividend for 2016 of DKK 4.60 for each Novo Nordisk A or B share
of DKK 0.20. The total dividend for 2016 of DKK 7.60 includes both the
interim dividend of DKK 3.00 for each Novo Nordisk A and B share of DKK
0.20 which were paid in August 2016 and a final dividend of DKK 4.60 for
each Novo Nordisk A and B share of DKK 0.20 to be paid in March 2017.
Elections
* Re-election of Göran Ando as chairman and Jeppe Christiansen as vice
chairman of the Board of Directors.
* Re-election of Brian Daniels, Sylvie Grégoire, Liz Hewitt and Mary Szela as
members of the Board of Directors.
* Election of Kasim Kutay and Helge Lund as new members of the Board of
Directors.
* Re-election of PricewaterhouseCoopers Statsautoriseret
Revisionspartnerselskab as the Company's auditor.
Shares and capital
* Reduction of the Company's B share capital by cancellation of part of the
Company's own holding of B shares. The Company's B shares are reduced by DKK
10,000,000 from DKK 402,512,800 to DKK 392,512,800. The Company's A share
capital of DKK 107,487,200 remains unchanged, whereby the Company's share
capital will amount to DKK 500,000,000.
* Authorisation to the Board of Directors to increase the Company's share
capital.
* Authorisation to the Board of Directors until the next Annual General
Meeting to allow the Company to repurchase own shares of up to 10% of the
share capital subject to a holding limit of 10% of the share capital.
Other
* Revised Remuneration Principles were adopted.
* Proposals from shareholders were not adopted.
Composition of the Board of Directors and its committees
After the Annual General Meeting, the Board of Directors held a board meeting to
appoint members of its committees.
The Board of Directors decided at the same time to establish a temporary
Research & Development Committee in light of the recently updated research and
development strategy and priorities. The Research & Development Committee will
assist the Board of Directors with oversight of the research and development
strategy, the pipeline and other tasks.
The Board of Directors, including its committees, are now composed as follows:
* Göran Ando (chairman of the Board, of the Nomination Committee and of the
Research & Development Committee)
* Jeppe Christiansen (vice chairman of the Board and chairman of the
Remuneration Committee)
* Brian Daniels (member of the Research & Development Committee)
* Sylvie Grégoire (member of the Audit Committee and the Research &
Development Committee)
* Liz Hewitt (chairman of the Audit Committee and member of the Nomination
Committee)
* Liselotte Hyveled (employee representative and member of the Research &
Development Committee)
* Kasim Kutay (member of the Nomination Committee and the Remuneration
Committee)
* Anne Marie Kverneland (employee representative and member of the
Remuneration Committee)
* Helge Lund (member of the Audit Committee and the Nomination Committee)
* Søren Thuesen Pedersen (employee representative and member of the Nomination
Committee)
* Stig Strøbæk (employee representative and member of the Audit Committee)
* Mary Szela (member of the Remuneration Committee)
Further information
Media:
Katrine Sperling +45 3079 6718 krsp(at)novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau(at)novonordisk.com
Investors:
Peter Hugreffe Ankersen +45 3075 9085 phak(at)novonordisk.com
Hanna Ögren +45 3079 8519 haoe(at)novonordisk.com
Anders Mikkelsen +45 3079 4461 armk(at)novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj(at)novonordisk.com
Company announcement No 20 / 2017
PR170323_AGM_resolutions_UK:
http://hugin.info/2013/R/2090103/789187.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 23.03.2017 - 16:15 Uhr
Sprache: Deutsch
News-ID 532151
Anzahl Zeichen: 5145
contact information:
Town:
Bagsvaerd
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 180 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Resolutions from the Annual General Meeting of Novo Nordisk A/S"
steht unter der journalistisch-redaktionellen Verantwortung von
Novo Nordisk A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
